Product Name |
Code |
Species Reactivity |
Application |
Size |
---|---|---|---|---|
SPP1 Recombinant Monoclonal Antibody |
CSB-RA022603MA1HU | Human | ELISA, FC | 100μl/50μl |
HIST1H4A Recombinant Monoclonal Antibody |
CSB-RA010429MA1HU | Human, Mouse, Rat | ELISA, WB, IHC, FC | 100μl/50μl |
ANPEP Recombinant Monoclonal Antibody |
CSB-RA001827MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
RHD Recombinant Monoclonal Antibody |
CSB-RA019677MA1HU | Human | ELISA, FC | 100μl/50μl |
CEACAM5 Recombinant Monoclonal Antibody |
CSB-RA005165MA3HU | Human | ELISA, IF, FC | 100μl/50μl |
FGFR1 Recombinant Monoclonal Antibody |
CSB-RA008642MA1HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
PLAUR Recombinant Monoclonal Antibody |
CSB-RA018122MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
LY6G6D Recombinant Monoclonal Antibody |
CSB-RA013246MA2HU | Human, Mouse, Rat, Macaca fascicularis | ELISA, FC | 100μl/50μl |
TM4SF1 Recombinant Monoclonal Antibody |
CSB-RA023615MA1HU | Human | ELISA | 100μl/50μl |
CD70 Recombinant Monoclonal Antibody |
CSB-RA004954MA1HU | Human | ELISA | 100μl/50μl |
CLDN4 Recombinant Monoclonal Antibody |
CSB-RA005506MA2HU | Human | ELISA, FC | 100μl/50μl |
ERBB2 Recombinant Monoclonal Antibody |
CSB-RA007763MA2HU | Human | ELISA, IHC | 100μl/50μl |
ALPG Recombinant Monoclonal Antibody |
CSB-RA001633MA1HU | Human | ELISA | 100μl/50μl |
STAT3 Recombinant Monoclonal Antibody |
CSB-RA022812MA1HU | Human | ELISA | 100μl/50μl |
IL2RA Recombinant Monoclonal Antibody |
CSB-RA011649MA1HU | Human | ELISA, IF | 100μl/50μl |
CLEC4C Recombinant Monoclonal Antibody |
CSB-RA855470MA1HU | Human | ELISA | 100μl/50μl |
DSG2 Recombinant Monoclonal Antibody |
CSB-RA622752MA1HU | Human | ELISA | 100μl/50μl |
CD69 Recombinant Monoclonal Antibody |
CSB-RA004952MA1HU | Human | ELISA | 100μl/50μl |
MYL9 Recombinant Monoclonal Antibody |
CSB-RA015318MA1HU | Human | ELISA | 100μl/50μl |
OSM Recombinant Monoclonal Antibody |
CSB-RA017260MA1HU | Human | ELISA | 100μl/50μl |
HMGB1 Recombinant Monoclonal Antibody |
CSB-RA010553MA1HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
MRAS Recombinant Monoclonal Antibody |
CSB-RA014781MA1HU | Human | ELISA, IHC, IF | 100μl/50μl |
GFAP Recombinant Monoclonal Antibody |
CSB-RA009369MA1HU | Human, Mouse, Rat | ELISA, WB, IHC, IF, FC | 100μl/50μl |
SNCA Recombinant Monoclonal Antibody |
CSB-RA021912MA1HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
CDH1 Recombinant Monoclonal Antibody |
CSB-RA005034MA1HU | Human, Mouse | ELISA, WB, IHC, FC | 100μl/50μl |
PTPRC Recombinant Monoclonal Antibody |
CSB-RA019049MA1HU | Human | ELISA, FC | 100μl/50μl |
ATP7B Recombinant Monoclonal Antibody |
CSB-RA002415MA1HU | Human | ELISA, IF, FC | 100μl/50μl |
CD19 Recombinant Monoclonal Antibody |
CSB-RA004888MA1HU | Human, Mouse | ELISA, WB | 100μl/50μl |
FTH1 Recombinant Monoclonal Antibody |
CSB-RA009030MA1HU | Human, Mouse | ELISA, WB, IHC, FC | 100μl/50μl |
HIST1H3A Recombinant Monoclonal Antibody |
CSB-RA010418MA1HU | Human, Mouse | ELISA, WB, IHC, IF | 100μl/50μl |
IL1R1 Recombinant Monoclonal Antibody |
CSB-RA011621MA1HU | Human, Mouse | ELISA, FC | 100μl/50μl |
MS4A1 Recombinant Monoclonal Antibody |
CSB-RA015007MA4HU | Human | ELISA, IHC, IF | 100μl/50μl |
GAPDH Recombinant Monoclonal Antibody |
CSB-RA009232MA1HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
TP53 Recombinant Monoclonal Antibody |
CSB-RA024077MA1HU | Human | ELISA, WB, IF, FC | 100μl/50μl |
TUBB1 Recombinant Monoclonal Antibody |
CSB-RA867148MA1HU | Human | ELISA, WB, IHC, FC | 100μl/50μl |
FCGR3A Recombinant Monoclonal Antibody |
CSB-RA008543MA1HU | Human | ELISA, IF | 100μl/50μl |
EGFR Recombinant Monoclonal Antibody |
CSB-RA159341MA1HU | Human | ELISA, IHC, FC | 100μl/50μl |
WDR5 Recombinant Monoclonal Antibody |
CSB-RA620753A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
GYPA Recombinant Monoclonal Antibody |
CSB-RA257220A0HU | Human | ELISA, FC | 100μl/50μl |
RAN Recombinant Monoclonal Antibody |
CSB-RA191819A0HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
GRIN1 Recombinant Monoclonal Antibody |
CSB-RA904344A0HU | Human | ELISA, FC | 100μl/50μl |
CLDN5 Recombinant Monoclonal Antibody |
CSB-RA037143A0HU | Human | ELISA, IHC | 100μl/50μl |
L1CAM Recombinant Monoclonal Antibody |
CSB-RA588962A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
HNF4A Recombinant Monoclonal Antibody |
CSB-RA571090A0HU | Human, Rat | ELISA, WB, IHC, IF, FC | 100μl/50μl |
TPSB2 Recombinant Monoclonal Antibody |
CSB-RA958088A0HU | Human, Mouse | ELISA, WB, FC | 100μl/50μl |
CREB1 Recombinant Monoclonal Antibody |
CSB-RA081853A0HU | Human, Mouse, Rat | ELISA, WB, FC | 100μl/50μl |
HSP90AB1 Recombinant Monoclonal Antibody |
CSB-RA644510A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
BCL6 Recombinant Monoclonal Antibody |
CSB-RA131953A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
malE Recombinant Monoclonal Antibody |
CSB-RA846828A0ENV | Escherichia coli, Human | ELISA, FC | 100μl/50μl |
ACTA1 Recombinant Monoclonal Antibody |
CSB-RA289956A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
A stable and highly specific antibody plays an important role in obtaining real and repeatable experimental results. It is a big headache if the antibody used in the experiment does not work. And what's even worse is that you use the antibodies to repeat the same experiment but get inconsistent results.
It is estimated that the annual loss in research funding due to the use of antibodies without enough validation is about $ 800 million worldwide. At the same time, it has caused countless experimental failures, and a waste of precious samples and researchers'youth.
Nowadays, the antibody validations information provided by antibody manufacturers and academic articles is very helpful for you to select high-quality antibodies. However, there is still an inevitable problem: whether it is polyclonal antibodies extracted from animal serum or monoclonal antibodies produced by hybridomas, there are more or fewer differences between batches. And recombinant antibodies may finally solve this problem.
Recombinant antibodies refers to the application of molecular cloning and gene mutation technology to transform a gene coding sequence of an antibody to produce superior performance of antibodies, also known as genetically engineered antibodies. Comparing with monoclonal antibodies generated in vivo of living animals through hybridoma technology, recombinant antibodies are a type of monoclonal antibodies which are produced in vitro by using synthetic genes.
In recent years, the use of recombinant antibodies is becoming increasingly wider and deeper in both therapeutics and diagnostics. With significant advantages over conventional antibodies, recombinant antibodies become more and more favored. The most important point is that recombinant antibodies can maximize the humanization to solve the heterogeneity between different species.
Generally speaking, recombinant antibodies can be divided into three classes, including chimeric antibody, humanized antibody, fully humanized antibody and small molecular antibody.
Compared with traditional antibodies, recombinant antibodies have the advantages of being irresistible, which is one of the reasons for their gradually emerging. Here, we present the advantages one by one as follows:
Because recombinant antibodies have these unprecedented advantages, recombinant antibodies fulfill a large spectrum of functions spanning from research to diagnosis and treatment therapies for various diseases. Their specificity and low immunogenicity make them a great alternative to traditional forms of treatment, increasing the accuracy of targeting specific molecules and avoiding adverse side effects.
Additionally, for recombinant antibodies production, it follows principally similar workflow. Generally, it consists of five steps: the construction of antibody gene library, phage display, the separation of antibodies, the modification of the isolated antibodies, and the scaling up of the production of selected antibodies in the cell culture expression system.
Although the processes of recombinant antibodies production are same as workflow, we need to recognize that there are several obstacles to the production of recombinant antibodies, such as lower antibody production, and highly trained and experienced technicians. Due to the complexity and intensive high technology of recombinant antibody production, most scientists need to obtain them from outsourcing companies.
Read the article, The Overview of Recombinant Antibody, for more information.
S Antibody referenced in "A magneto-optical biochip for rapid assay based on the Cotton–Mouton effect of γ-Fe2O3@ Au core/shell nanoparticles", Journal of nanobiotechnology, 2021.
SARS-CoV-2 Spike RBD Nanobody referenced in "Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2", Bioorganic & Medicinal Chemistry, 2021.
HIF1A Antibody, CASP3 Antibody referenced in "PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia", Cancer cell international, 2021.
Phospho-ERN1 (S724) Antibody referenced in "The ER stress sensor inositol-requiring enzyme 1α in Kupffer cells promotes hepatic ischemia-reperfusion injury", Journal of Biological Chemistry, 2021.
CDK4 Antibody and CDK6 Antibody referenced in "Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells Via Forkhead Box M1 Suppression", Journal of Cancer, 2021.
BIRC5 Antibody referenced in "LTBP4 Inhibits the Proliferation and Metastasis in Melanoma by Activating Hippo-YAP Signaling", Research Square, 2020.